Bone metastasis may account for the high FGF23 levels and symptoms of TIO observed in patients with prostate cancer according to other studies (Nakahama et al., 1995; Cotant and Rao, 2007; Chiam et al., 2013). Here, FGF23 is linked to prostate cancer.